CYAD-211

N/A

Report date: 2022/12/26 13:40:38

Base Information

Drug NameCYAD-211

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionImmunologic cytotoxicityT lymphocytes stimulantsAnti-BCMA

TargetsB-cell maturation protein

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesCelyad Oncology SA

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCelyad Oncology SA

Active IndicationsN/A

Inactive IndicationsMultiple Myeloma

Other Information

ATC CodeN/A